Section 232 Drug Tariffs Aren’t Health Policy

Executive Summary The Trump Administration announced a new Section 232 tariff regime targeting patented pharmaceuticals and associated pharmaceutical ingredients, tying the policy to both manufacturing onshoring and most-favored-nation pricing metrics. The proclamation establishes a default 100 percent tariff on identified patented drugs and related inputs, a 20 percent tariff rate for companies with Department of […]